Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Baxter International Inc. (NYSE: BAX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Baxter is a global medtech company with common stock and certain global notes registered under Section 12(b) of the Exchange Act, and its filings offer insight into capital structure, financing activities, governance and key business developments.
Investors reviewing Baxter’s filings will find Form 8-K reports covering topics such as new senior note offerings due 2029, 2030 and 2035, amendments to credit agreements, tender offers for existing senior unsecured notes due 2026 and 2027, and repayment of a term loan facility. Other 8-Ks detail changes in executive leadership, earnings press releases furnished under Item 2.02, and updates to leverage covenants. These documents outline how Baxter manages its debt profile, liquidity and capital allocation, including refinancing transactions and tender offer results.
Baxter’s filings also confirm its status as a Delaware corporation and list its securities registered on the New York Stock Exchange, including common stock under the symbol BAX and 1.3% global notes due 2029. Disclosures about note terms, ranking, optional redemption provisions, change-of-control repurchase rights and covenants are contained in indentures and supplemental indentures referenced in the exhibits to Form 8-K.
On Stock Titan, AI-generated highlights help users quickly identify key points in Baxter’s 10-K and 10-Q reports (when available), such as segment information, risk factors and liquidity discussions, while Form 4 insider transaction filings can be used to monitor trading by directors and officers. Real-time updates from EDGAR ensure that new Baxter filings appear promptly, and AI summaries provide plain-language explanations of technical sections, helping users understand what each filing may mean for Baxter’s financial obligations, governance and strategic actions.
Baxter International EVP and CFO Joel T. Grade reported a routine tax-withholding share disposition. On March 6, 2026, 8,153 shares of common stock at $17.69 per share were forfeited to cover taxes triggered by the settlement of vested restricted stock units, not through an open-market sale. After this withholding, he directly holds 271,674 shares.
Hider Andrew P. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International President and CEO Andrew P. Hider reported awards of equity-based compensation. He received 488,506 stock options and 201,804 shares of common stock as a grant, both at a price of $0.00 per share. The stock grant consists of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to vesting conditions under Baxter’s 2021 Incentive Plan. The options become exercisable on the same three-year schedule starting March 1, 2027.
Carlisle Cynthia reported acquisition or exercise transactions in this Form 4 filing.
Baxter International reported that Executive Vice President and CHRO Cynthia Carlisle received new equity awards. She was granted stock options for 43,103 shares, which become exercisable in three equal annual installments beginning on March 1, 2027. She also received 17,806 restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, and an additional 11,871 restricted stock units scheduled to vest on February 27, 2029, all subject to vesting conditions under the company’s 2021 Incentive Plan.
Baxter International executive Reazur Rasul reported a tax-related share disposition. On March 2, 2026, 1,614 shares of common stock at $19.69 per share were forfeited to cover withholding taxes triggered by the settlement of vested restricted stock units granted on March 1, 2023. After this tax-withholding disposition, Rasul directly owned 138,231 Baxter shares.
Baxter International executive Maria Cecilia Soriano reported equity compensation changes involving common stock and options. On February 27, 2026, she acquired 23,742 shares of common stock at $0.00 per share as a grant, and received a stock option award covering 57,471 shares, also at $0.00 per share. These restricted stock units and options are scheduled to vest or become exercisable in three equal annual installments beginning on March 1, 2027, subject to the vesting requirements of Baxter’s 2021 Incentive Plan. On March 2, 2026, she disposed of 1,852 shares of common stock at $19.69 per share to cover taxes due on previously vested restricted stock units, leaving her with 77,894 common shares directly held.
Baxter International EVP and General Counsel David S. Rosenbloom reported equity compensation changes and related tax withholding. On February 27, 2026 he received 26,709 shares of common stock and a grant of 64,655 stock options, both at $0.00 per share as awards scheduled to vest in three equal annual installments beginning on March 1, 2027 under Baxter’s 2021 Incentive Plan. On March 2, 2026, 1,336 common shares at $19.69 per share were forfeited to cover taxes from the settlement of previously vested restricted stock units. After these transactions he directly owned 144,837 common shares and 64,655 stock options.
Grade Joel T. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International executive vice president and CFO Joel T. Grade reported equity awards rather than open-market trades. He received stock options for 103,448 shares at a price of $0.0000 per share and a grant of 42,735 shares of common stock.
The common stock grant represents restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to the vesting conditions in Baxter’s 2021 Incentive Plan. The options become exercisable in three equal annual installments starting on the same date. Following these grants, Grade directly holds 279,828 common shares, including shares in the employee stock plan.
Zielinski Anita A reported acquisition or exercise transactions in this Form 4 filing.
Baxter International senior vice president, chief accounting officer and controller Anita A. Zielinski reported receiving an equity award of 30,864 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. These units are scheduled to vest in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date, subject to the vesting conditions in Baxter’s 2021 Incentive Plan. After this award and dividend reinvestments, Zielinski now directly holds 48,214 shares of Baxter common stock.
Baxter International Inc. executive vice president and chief human resources officer Cynthia Carlisle filed an initial statement of beneficial ownership of securities. The Form 3 indicates she held no shares of Baxter common stock directly following the reported date, establishing a baseline for future ownership disclosures.
McDonnell Michael R. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International director Michael R. McDonnell reported receiving a grant of 1,811 shares of Baxter common stock. The shares were granted at a price of $0.0000 per share and are described as fully vested, subject to the applicable grant terms and conditions. Following this award, McDonnell holds 1,811 shares of Baxter common stock directly.